The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in ...

Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to ...

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with ...

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at ...

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time ...

Atorvastatin reduce​​d​​ major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or ...

Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to ...

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and ...

Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults ...